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Abstract
Background: The Magpie Trial compared magnesium sulphate with placebo for women with pre-
eclampsia. 10,141 women were recruited, 8804 before delivery. Overall, 9024 children were
included in the analysis of outcome at discharge from hospital. Magnesium sulphate more than
halved the risk of eclampsia, and probably reduced the risk of maternal death. There did not appear
to be any substantive harmful effects on the baby, in the short term. It is now important to assess
whether these benefits persist, and to provide adequate reassurance about longer term safety.
The main objective of the Magpie Trial Follow Up Study is to assess whether in utero exposure to
magnesium sulphate has a clinically important effect on the child's chance of surviving without major
neurosensory disability. Other objectives are to assess long term outcome for the mother, and to
develop and assess appropriate strategies for following up large numbers of children in perinatal
trials.
Study design: Follow up is only feasible in selected centres. We therefore anticipate contacting
2800–3350 families, for 2435–2915 of whom the woman was randomised before delivery. A further
280–335 children would have been eligible for follow up if they had survived. The total sample size
for the children is therefore 3080–3685, 2680–3210 of whom will have been born to women
randomised before delivery.
Families eligible for the follow up will be contacted, and surviving children screened using the Ages
and Stages Questionnaires. Children who screen positive, and a sample of those who screen
negative, will whenever possible have a paediatric and neurodevelopmental assessment. When
women are contacted to ask how their child is, they will also be asked about their own health. The
primary outcome is a composite measure of death or neurosensory disability for the child at 18
months.
Discussion: The Follow Up Study began in 2002, and now involves collaborators in 19 countries.
Data collection will close at the end of 2003.
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Background
Pre-eclampsia, a multisystem disorder of pregnancy usu-
ally associated with raised blood pressure and proteinuria,
complicates 2–8% of pregnancies [1]. Although outcome
is often good, pre-eclampsia is a major cause of morbidity
and mortality for women and children [2,3]. It accounts
for 10% of maternal deaths, and is also associated with
increased perinatal mortality [4,5]. Eclampsia, the occur-
rence of seizures superimposed on pre-eclampsia, is rare.
It affects 1 in 100 [6] to 1 in 2000 [7] deliveries, but is
associated with a considerable increase in morbidity and
mortality [7].
Magnesium sulphate is the anticonvulsant of choice for
treating eclampsia [8-10]. The Magpie Trial has demon-
strated it is also effective for preventing eclampsia [11,12].
Overall, this study recruited 10,141 women with pre-
eclampsia. There was more than a halving in the risk of
eclampsia (relative risk (RR) 0.42, 95% confidence inter-
vals (CI) 0.29 to 0.60) associated with the use of magne-
sium sulphate rather than placebo. The risk of maternal
death was also reduced, although this did not reach statis-
tical significance (RR 0.55, 95% CI 0.26 to 1.14) [12].
There do not appear to be substantive harmful effects for
the mother or baby, in the short term. In particular, there
is reasonable reassurance that there was no clinically
important effect on the risk of the baby dying before dis-
charge from hospital or being in a special care nursery for
more than 7 days (RR 1.02, 95% CI 0.95 to 1.09) [12].
It is now important to assess whether these benefits per-
sist, and to provide adequate reassurance about longer
term safety. The need for caution when interpreting data
on short term outcome alone was highlighted recently by
the long term follow up of babies at risk of chronic lung
disease, or with established chronic lung disease, who
were treated with early high-dose dexamethasone after
birth [13]. Because trials quickly showed there were obvi-
ous short term benefits, including reductions in ventilator
and oxygen dependence and in chronic lung disease, ster-
oids were increasingly adopted world-wide, for more than
fifteen years. When studies with long term follow up were
eventually reported they showed no significant increase in
the overall number of long term survivors, but some
reported a clear increase in the number of survivors with
cerebral palsy [14].
Magnesium sulphate is associated with cerebral vasodila-
tation, and is a blocker of N-methyl-D-aspartate (NMDA)
receptors in the brain, the pathway for anoxic cell damage.
Magnesium sulphate could therefore effect later neurode-
velopment of children exposed in utero. Potential effects
on the baby may also depend on gestational age at expo-
sure to magnesium sulphate. Case control studies have
suggested that maternal magnesium sulphate administra-
tion reduces the risk of cerebral palsy for low birthweight
(<1500 g) infants, [15-17] although a recent study sug-
gests such exposure may actually increase cerebral palsy
[18]. There is also concern about a possible increase in
paediatric mortality following exposure to magnesium
sulphate [19]. For low birthweight babies in utero expo-
sure may therefore be associated with 'survival of the fit-
test', although this has been disputed [20]. As the
aetiology of cerebral palsy is different for preterm and
term babies, even if the reduction in cerebral palsy for the
former is real, we cannot assume there will be similar ben-
efits for term babies.
The hypothesis that magnesium sulphate reduces the risk
of cerebral palsy for preterm babies is being tested in
ongoing trials in which women at risk of very preterm
birth are randomised to magnesium sulphate or placebo
[21,22]. These studies will recruit relatively few women
with pre-eclampsia, however, and will not provide evi-
dence on the effects of exposure nearer to term. Data from
the first of these studies are now available [23]. In this
study 1062 women at risk of delivery before 30 weeks ges-
tation were allocated either magnesium sulphate or pla-
cebo. There was a moderate, although non-significant,
reduction in the risk of death or cerebral palsy (RR 0.83,
95% CI 0.66 to 1.03). There was, however, a significant
reduction in the proportion of children with substantial
gross motor dysfunction (RR 0.51, 95% CI 0.29 to 0.91).
Magnesium sulphate is already widely used. In the light of
data from the Magpie Trial [12] on outcome at discharge
from hospital, its use is likely to increase in years to come.
The Magpie Trial Follow Up Study aims to provide reliable
information about the longer term outcome for women
and children. As there are relatively few reliable data
about the morbidity and mortality associated with pre-
eclampsia, these data will also enhance our understanding
of the long term implications of pre-eclampsia.
Trial design
Objectives
The main objective is to assess whether in utero exposure
to magnesium sulphate has a clinically important effect
on the child's chance of surviving without major neuro-
sensory disability. The specific hypotheses are whether
exposure to magnesium sulphate affects:
• the risk of the child dying
• the risk of severe cerebral palsy
• the risk of blindness or deafness
• the risk of developmental delayBMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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For some children we also aim to collect information that
will allow us to compare less severe, but nevertheless
important, differences in developmental progress
between the two treatment groups. In addition, we will
assess whether magnesium sulphate has any longer term
impact on outcome for the women.
Other objectives are to explore the long term conse-
quences of pre-eclampsia, and risk factors for adverse out-
come, for both the woman and her child. Also, to develop
and assess affordable and appropriate strategies for follow
up of large numbers of children recruited to perinatal tri-
als, particularly in low and middle income countries. We
will develop and evaluate strategies for using the Ages and
Stages Questionnaires (ASQ) [24] in Latin America, Africa
and Asia. We will also modify the ASQ [24] into a simple
low cost tool for use in low income countries, and assess
its performance.
Study sample
The Magpie Trial recruited 10,141 women at 175 centres
in 33 countries. Five women were excluded from the ini-
tial analyses, 4 because no data were available and 1
woman was entered into the wrong trial. Of the remaining
10,136, 8799 women (87%) were randomised before
delivery, and 1337 (13%) were randomised in the first 24
hours after delivery. Outcome at discharge from hospital
was available for 10,110 women, 8775 (87%) of whom
were randomised before delivery. These 8775 women
gave birth to 9153 babies, of whom 9024 (98.6%) were
included in the analysis of outcome up to discharge from
hospital. Overall, 7883 of the children whose mothers
were randomised before delivery were alive at discharge
from hospital, and for another 2 our last information was
that they were still in hospital.
The 1337 women randomised after delivery gave birth to
1418 babies, of whom 143 (10%) were stillbirths or neo-
natal deaths.
For a variety of reasons, follow up is not possible at some
centres. In others, due to the difficulty of tracing women,
only those randomised in the last year of recruitment
(December 2000–November 2001) will be contacted.
Overall, we estimate 2800–3350 families will be eligible
for assessment in the Follow up Study, regardless of
whether recruitment was before or after delivery. A further
280–335 children would have been eligible for the follow
up study if they had survived until discharge.
For the main objective, assessing the effects of in utero
exposure to magnesium sulphate, the analyses will
include only children whose mothers were randomised
before delivery. The assessment of long term outcome for
the woman will include data for all women, regardless of
whether randomisation was before or after delivery.
Assessment of the ASQ will also be based on data for all
children.
Sample size
Overall, we estimate 2800–3350 families will be eligible
for assessment in the Follow up Study. A further 280–335
children would have been eligible for the follow up study
if they had survived until discharge, and the total sample
size for the children is therefore 3080–3685.
For children who were alive at discharge from hospital
outside the UK, we anticipate 20% loss to follow up. For
the 800 children in the UK we expect <1% losses to follow
up (for mortality). In the UK, although non-response to
the ASQ may be 10% some information about serious dis-
ability will be available from general practitioners. Loss to
follow up for disability in the UK is therefore likely to be
0–5%. So, we expect to have data for 2400–2840 children
who were alive at discharge from hospital, 2090–2475 of
whom will have been born to women randomised before
delivery. In total, this means we will have data on death or
disability for 2680–3175 children, 2370–2810 of whom
will have been born to women randomised before
delivery.
Many of these children are high risk. For example, one
third of births were <34 weeks. In the UK 94% of these
very preterm babies survived until discharge from hospi-
tal, outside the UK 80% survived. We anticipate a further
3–5% of children may die after discharge, 15–25% of chil-
dren may screen positive on the ASQ, [24,25] of whom
30–40% [24] may have neurosensory disability con-
firmed. This suggests that the composite primary outcome
(death or neurosensory disability) may affect 20–25% of
children in the placebo group. Power to detect a range of
clinically important reductions in the treatment group are
illustrated in table 1.
Even when adjusted for expected losses to follow up, the
anticipated sample size of 3080–3685 children, of whom
2680–3210 will have been born to women randomised
before delivery, will provide adequate power to detect a
relative difference between the groups of at least 20% in
the composite primary outcome.
How many screen negative children do we need to assess?
We anticipate assessing 450–550 screen negative children
and, at best, may be able to increase this to 700–800 chil-
dren. Confidence intervals for a range of possible false
negative rates in a sample of 500 screen negative children
are shown in table 2.BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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Outcome measures
The most extreme outcomes for the child are death, and
then major neurosensory disability. The two are not inde-
pendent, as children with major neurosensory disability
have a high mortality and, particularly for children born
too early, reduction in mortality may be at the cost of an
increase in neurosensory disability. The primary outcome
for this follow up study is the composite outcome of death
or major neurosensory disability at 18 months.
Secondary outcomes for the baby are death alone, each of
the individual measures of neurosensory disability alone,
delayed speech, other important disability and contact
with health services. Developmental attainment will be
compared across the treatment groups for the subset of
children for whom these data are available. Outcomes for
the mother are death or serious morbidity potentially
related to pre-eclampsia, other serious morbidity, hyper-
tension requiring treatment, any reported hypertension,
subsequent pregnancies and their outcome, and contact
with health services.
Definition of the primary outcome
Our definition of death or major neurosensory disability
needs to take account of several complex issues. These
include the wide range of duration of follow up for each
child, age at death, how severe the disability has to be, and
what age does a child have to be before anyone can be
confident that s/he does, or does not have, such disability.
To ensure that our primary outcome is clear and unambig-
uous, we define below death and neurosensory disability.
Such a composite end point needs to be expressed at a sin-
gle concordant age. The time point of 18 months (cor-
rected for gestation at birth) was chosen because it strikes
the best balance between feasibility of follow up and cer-
tainty in the diagnosis of neurosensory disability. Chil-
dren who are assessed when they are older then 18
months will be included in the primary outcome. For
example, if a child is assessed as having neurosensory dis-
ability when s/he is 24 months, or older, it is reasonable
to assume that this would have been diagnosed at 18
months, had the child been seen then. Conversely, if a
child seen at 24 months has no neurosensory disability, it
is reasonable to assume the same would have been true at
18 months. However, if there was an obvious cause for the
neurosensory disability, such as trauma or meningitis,
that occurred when the child was older than 18 months,
the child would be excluded from the analysis of the pri-
mary outcome (these children would be included in
'other disabilty', see below). Data for children assessed at
12–17 months of age will also be included in the primary
outcome. If a child of 12 months is blind, deaf or unable
to sit without support (developmental progress suggestive
of cerebral palsy), s/he is likely to have the composite pri-
mary outcome by the age of 18 months. Surviving
Table 1: Sample sizes for a range of power calculations for the composite primary outcome
25% reduction in risk of death or neurosensory disability
18%→13.5% 20%→15% 22%→16.5% 24%→18%
alpha 0.05, power 90% 2840 2500 2230 2000
alpha 0.05, power 80% 2140 1890 1684 1512
20% reduction in risk of death or neurosensory disability
18%→14.4% 20%→16% 22%→17.6% 24%→19.2%
alpha 0.05, power 80% 3390 2990 2664 2390
alpha 0.05, power 70% 2376 2114 2114 1896
15% reduction in risk of death or neurosensory disability
18%→15.3% 20%→17% 22%→18.7% 24%→20.4%
alpha 0.05, power 60% 3870 3410 3036 2722
Table 2: Confidence intervals for a range of possible false negative rates in a sample of 500 screen negative children
Observed false negative rate
(% of cases among screen negatives)
N = 500
(95% confidence interval)
5% 3.4% to 7.3%
2% 1.1% to 3.6%
1% 0.4% to 2.3%
0% 0% to 0.8%BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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children assessed only when less than 12 months old will
not be classified as to whether or not they have neurosen-
sory disability, as they are too young for any such judge-
ment to be reliable. Deaths when the child is older than
18 months will not be included in the analysis of primary
outcome.
Death
Deaths from defects arising during conception or embry-
ogenesis will be excluded from the main analysis, but will
be included in a sensitivity analysis. Ideally only children
who were alive in utero at the time the woman was ran-
domised will be included. Unfortunately this was not
always known for certain in the Magpie Trial. The analysis
of deaths will therefore exclude babies who were likely to
have died in utero before trial entry. These are those for
whom the fetal heart beat was not heard at trial entry, and
who were a macerated stillbirth within 24 hours after trial
entry. This same exclusion was used in the main study
report [12]. Children who died after trial entry but before
discharge from hospital, who would have been selected
for follow up had they survived, will be included in the
sample.
Neurosensory disability
Currently, there is no internationally agreed consensus on
what constitutes 'major disability', or how it should be
assessed. Our definition of major neurosensory disability
is therefore based on commonly agreed components,
combined with a pragmatic view of what is likely to be
feasible and sensible to measure. For this study we defined
major neurosensory disability as the presence of one or
more of severe cerebral palsy, blindness, deafness, and
severe developmental delay. Disability due to defects aris-
ing during conception or embryogenesis will be excluded
from the main analysis, but will be included in a sensitiv-
ity analysis.
We have included only severe cerebral palsy in our defini-
tion of major neurosensory disability. Although the diag-
nosis of cerebral palsy is problematic for younger
children, our aim is to detect children with major func-
tional abnormalities, which can be done at an early age
[26]. Cerebral palsy will be diagnosed if the child has non-
progressive motor impairment characterised by abnormal
muscle tone and a decreased range or control of move-
ments. For example, most healthy children are sitting con-
fidently, and unsupported, by 8 months (corrected for
gestation) while those with severe cerebral palsy are not
doing this by 12 months. Whenever possible, we will also
classify children who were 12 months or older as likely to
have mild, moderate or severe cerebral palsy. For example,
at 2 years of age severe cerebral palsy will include non-
ambulant children who are never likely to walk, moderate
cerebral palsy will include non-ambulant children who
are expected ultimately to walk independently, and mild
cerebral palsy will include ambulant children at 2 years of
age. This will increase the clinical relevance of our results,
and facilitate amalgamation of our data with those from
other relevant trials [21,22].
Studies have differed over whether to take a developmen-
tal quotient of either more than two standard deviations
or more than three standard deviations below normal as
an indication that a child has 'severe disability' [27]. We
have defined severe developmental delay as being more
than two standard deviations from the mean, which indi-
cates progress is only what would be expected of a child
two thirds that age. For example, this would assess a child
who could not walk unaided at two as comparably disa-
bled to a child who could not sit unaided by twelve
months (corrected for gestation). This has the advantage
of simplifying the amalgamation of the results from cen-
tres that assess children at different ages.
Blindness is defined as binocular visual acuity of less than
6/60. Deafness is defined as a hearing loss of 50 dB or
more in the better ear. In practise this is the threshold at
which children normally benefit from a hearing aid
(although there will, of course, be a few children so deaf
that an aid offers little benefit).
Severe developmental delay will be defined on the revised
Bayley Scales of Infant Development (BSID-II) [28] as a
Mental Development Index (MDI) score <70 (>2 SD
below mean of 100) [28]. On the Griffiths Scale, [29]
severe developmental delay will be defined as a global
developmental quotient (DQ) of >2 SD below the mean.
Equivalent definitions will be applied to the Denver
Developmental Screening Test-2 (DDST-II), [30] and its
derivatives.
Likely disability
We anticipate data will be incomplete for some children,
therefore there will also be a category of 'likely disability'.
This will include: children for whom data are incomplete
(such as children with significant developmental delay
not subjected to formal qualitative developmental assess-
ment), and those assessed at 12–17 months, for whom
major disability seems likely as assessed by 2 independent
experts. These children will be included in the primary
outcome.
Definitions of secondary outcomes for the child
Other disability
Our definition of 'other disability' will include two groups
of children: those with non-neurosensory disability and
those with mild-moderate neurosensory disability.BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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It has been argued that indicators of non-neurosensory
disability should be included within a broad inclusive def-
inition of 'severe disability' [27]. Examples of non-neuro-
sensory disability include the need for continuous
supplemental oxygen, breathing support, renal dialysis,
and tube or parenteral feeding. The provision of such
treatments is variable and discretionary, however, so that
even though their provision definitely indicates disability,
it seems better not to include them in the definition
adopted for the Magpie Trial. The same might, on prag-
matic grounds, also be said about taking "the presence of
seizures more than once a month despite appropriate
treatment" as another objective marker of severe disabil-
ity. In practice, most children with these problems will
have already been classified as having a 'severe disability'
on other grounds. We will report children who have these
problems. Those who also meet our definition, above, of
neurosensory disability, will be included in our primary
outcome. Those who do not will be included in the sec-
ondary outcome of 'other disability'.
It is sometimes difficult to identify with certainty mild to
moderate disability in children less than two years old.
Study centres will therefore be encouraged to assess as
many children as possible at 24 months, or more, after
they were due to be born. In some collaborating centres
this will not be feasible. So, when assessing whether a
child has mild to moderate disability all information on
children assessed 18 months, or more, after they were due
to be born will be used. Also, as most children will only
be assessed in more detail if they 'fail' the ASQ, there may
be some under ascertainment of this more moderate disa-
bility. There is, however, no reason why ascertainment
should differ in the two treatment groups.
Our definition of other disability will include any child,
aged 18 months or more:
• with non-severe cerebral palsy
• with reduced mobility – even if not identified as having
cerebral palsy
• having more than 1 seizure a month despite treatment
• unable to feed themselves for any reason after 2 years of
age
• having a Bayley Psychomotor Developmental Index
(PDI) score >2 SD below normal
• with other disability not included in neurosensory disa-
bilty (see above)
Delayed speech
Isolated speech delay is not uncommon. When language
comprehension is good, however, there is seldom a last-
ing problem. We will therefore report how many children
in each treatment group had a vocabulary of less than 10
words at two years, or more, after they were due to be
born, but have no other reason for being classified as hav-
ing a disability. This analysis will be restricted to children
assessed when they were at least 24 months old, as lan-
guage development for younger children is very variable.
Contact with health services
The number and reasons for clinic attendance and hospi-
tal admission will be compared between treatment
groups.
Definitions of secondary outcomes for the mother
Death of the women
This will include all deaths after discharge from hospital
and those before discharge from hospital of women who
would have been selected for follow up, had they
survived.
Serious morbidity for the women, potentially related to pre-eclampsia
Serious maternal morbidity will include women with
eclampsia or other serious morbidity potentially related
to pre-eclampsia before discharge from hospital, as well as
those with serious morbidity after discharge. Serious mor-
bidity potentially related to pre-eclampsia before dis-
charge was pre-defined as one or more of respiratory
depression, respiratory arrest, pneumonia, cardiac arrest,
coagulopathy, renal failure, liver failure, pulmonary
oedema and cerebral haemorrhage. Serious morbidity
after discharge will include renal problems, stroke, and
severe hypertension.
Other serious morbidity
Other serious morbidity will include women with throm-
boembolic disease, major psychiatric problems, major
infection, and cancer.
Hypertension for the women
Hypertension will be defined as any raised blood pressure
since discharge sufficient to require antihypertensive treat-
ment. Those women taking antihypertensive treatment at
the time of assessment will also be reported.
Reproductive morbidity
Reproductive morbidity will include miscarriage, ectopic
pregnancy, and gynaecological problems.
Contact with health services
The number and reasons for clinic attendance and hospi-
tal admission will be compared between treatment
groups.BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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Assessments
How the children will be assessed
The main aim of the follow up study is to investigate any
effect of magnesium sulphate on death or major neuro-
sensory disability in the surviving children. In many coun-
tries the only way to check whether the child is still alive
will be to contact the family. As well as being a means of
finding out whether the child is alive, this makes it possi-
ble to find out how the child is progressing, and will also
provide information about the health status of the
mother. All assessments of women and children will be
made blind to treatment group.
Children will be screened for serious disability using the
ASQ, [24] or a shortened version of the ASQ (see below).
In the UK and other developed countries the question-
naires will be sent to the family by post. Elsewhere, the
questionnaires will be administered by telephone, in a
clinic, or during a home visit. If the family has moved and
cannot be contacted, information will be collected, when-
ever possible, from neighbours. If the woman is invited to
attend a clinic this will be to a dedicated clinic to reduce
waiting time. These clinics may provide a package of
appropriate health care, such as family planning or immu-
nisation, to encourage attendance. The family's travelling
expenses will be reimbursed.
When the children will be assessed
Neurosensory disability (a serious problem with vision,
hearing or movement control) can be recognised with
some confidence within 18 months of birth, especially if
any preterm baby is only examined 18 months after the
expected date of birth. We will therefore encourage our
collaborators to assess as many children as possible when
they are 18 months, or more. The age at which first contact
is made with the family will be determined locally, and
will primarily depend on what is feasible. It is not possible
to contact and assess the children at a single age across the
study. We will therefore take the pragmatic approach that
any information about outcome after discharge from hos-
pital is better than none. For children being assessed when
they are less than or equal to 24 months and who were
born before 37 completed weeks, an adjustment will be
made for gestation at birth.
When the mothers will be assessed
To contact the child it is usually necessary to contact the
mother. The women will be asked a few simple questions
about their own health, at the same time as any assess-
ment of their child. Whether mothers of children who
died are contacted will be at the discretion of the local col-
laborators in consultation with their ethics committee.
How outcome will be assessed
Screening with the ages and stages questionnaires
Children will be screened using the Ages and Stages Ques-
tionnaires (ASQ) [24]. The ASQ [24] is a series of 19 ques-
tionnaires designed to be completed by parents or
primary caregivers, but they perform equally well if com-
pleted with assistance from a researcher or a health care
worker. The questionnaires are validated for intervals
from 4 months-5 years, adjusted for gestation at birth up
to 24 months. Each is valid for eight weeks, four weeks
either side of the target age.
Each of the 19 age-targeted questionnaires contains 30
developmental questions covering five domains: commu-
nication, gross motor, fine motor, problem solving and
personal-social. An additional section has 8 questions
addressing general parental concerns. The questionnaires
are written in simple, straightforward language and illus-
trations assist parents in understanding some items. For
each developmental item the response requested is 'yes',
'sometimes' or 'not yet'. To score the responses, each is
converted to a point value, which is totalled within the
domain, and the totals are compared to established
screening cut-off points. If one or two questions in a
domain have not been answered, a ratio score can be com-
puted. If more than two items are omitted, the domain
cannot be scored. If one or more domains could not be
scored, the child will be treated as screen positive, and
invited to have a full assessment. If the ASQ is completed
outside the 8 week window for which it is valid (see
above), this will also be treated as 'screen positive'. The 18
month questionnaire is appendix 1 [Additional file: 1].
The ASQ can accurately identify children who may have
developmental disorders, and therefore need further eval-
uation. Reported sensitivity for mild to moderate develop-
mental delay ranges from 38–90%, and specificity ranges
from 81–91% [24]. Positive predictive value ranges from
32–64% [24]. Factors in this variation between question-
naires include random errors, and how well the test per-
forms at each age. For questionnaires at 12–24 months,
sensitivity is reported to range from 65% to 85% and spe-
cificity from 81% to 90%. Our expectation is that the ASQ
will have a high sensitivity and negative predictive value
in our population. For example, a child who is completely
blind, or completely deaf, or has severe cognitive delay or
severe cerebral palsy will fail at least one domain within
the ASQ, and so will be screen positive. Overall sensitivity
to identify delayed development is 72%, but when used to
identify children with established developmental delay
sensitivity has been shown to be higher, at 96%, [24] and
for ex-preterm children it is 90–100% [25].
The ASQ has major advantages for use in large interna-
tional trials. It is flexible, being validated for use across aBMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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range of ages and cultures, although primarily in North
America, and for both preterm [25] and term children
[24]. It is available in English, Spanish and French. Per-
formance is not reduced if the interviewer paraphrases the
exact wording, or if culturally inappropriate questions are
altered or dropped [24]. It is also low cost. The age at
which children are assessed can be tailored to the needs of
individual centres, so no child should be lost to follow up
merely because it was not possible to contact the family
within a narrow time window.
Shortened ages and stages questionnaires
For centres where use of the full ASQ is not feasible, we
have developed shorter ASQs for 8, 10, 12, 14, 16, and 18
months. To facilitate administration, these are provided
to collaborators in a booklet (see 1). Additional short
ASQs are available up to 36 months. The shortened ASQ
uses three questions in each of three domains: gross
motor, communication and problem solving, with 5 over-
all questions. To pass, the child must achieve at least one
'yes' in each domain. The use of 38 questions in the full
ASQ is designed primarily to identify moderate or subtle
delay in development. Reducing the number of questions
may reduce performance for these more subtle effects, but
this small number of questions should still be adequate
for detecting gross abnormalities [31].
Children who screen positive on the ages and stages questionnaires
As severe disability has a low prevalence, positive predic-
tive values are likely to be at the low end of the reported
range. We cannot therefore assume that all screen positive
children are indeed severely disabled. The screen positive
children will thus be invited for a clinical and neurodevel-
opmental assessment using the Bayley Scales of Infant
Development [28] or the Griffiths Tests [29]. If neither of
these can be used, an alternative test may be used. If no
test is feasible, we will rely on clinical history and exami-
nation alone. Families will not be told their child has
'failed' the screen, as this would cause unnecessary con-
cern. They will be invited to have the assessment in a way
that is as convenient as possible for them.
Children who screen negative on the ages and stages questionnaires
Our aim is to identify children with severe disability. It is
reasonable to assume that the ASQ will have a higher neg-
ative predictive value when used to identify severe disabil-
ity, than when used to identify mild developmental delay.
We will test this assumption by assessing a sample of
screen negative children. In the UK, sample selection will
be based on geographic location at trial entry. Outside the
UK, some centres will assess all screen negative children.
Others will assess a predefined sample.
Dealing with the family when the child has severe disability
The ASQ is a screening tool, and many of the children
who fail the questionnaire (screen positive) will be nor-
mal. Due to this risk of being false positive, parents and
carers will not be told the child has a problem based on
the ASQ alone. Many of the children with disability in the
study will already have been identified by the health serv-
ices, and the family or carer will be aware of the child's
problems and diagnosis. In this situation, the family
should be dealt with sensitively. The child should not be
required to have any unnecessary testing, and any ques-
tions or concerns should be responded to.
The study may identify some children with severe disabil-
ity who, despite their considerable problems, have not yet
been detected by the health services. It is likely that the
family or carer of such a child will be aware of the child's
difficulties. The diagnosis of severe disability will usually
be made by the paediatrician doing the assessment. S/he
should then explain it to the family, as would happen in
normal clinical practice. If it is appropriate to refer the
child to additional health services, and the family agree,
this should again be done in accordance with normal clin-
ical practice. If necessary, the Magpie Trial Co-ordinating
Centre should be contacted for advice.
Ethics approval and consent
The information leaflet given to women before they gave
consent to recruitment to the Magpie Trial stated that
women might be contacted later to find out how they and
their child are. In some countries ethics committees have
agreed women need not be asked again for consent to
being followed up. All women and carers have the option
to opt out of the study, if they wish. Some centres prefer
to ask the women to consent again to the follow up study.
This decision should be made in consultation with the rel-
evant local ethics committee.
Data management
Data will be processed and cleaned as they accumulate.
Queries will be discussed with the local co-ordinator
whenever possible. There will be no interim analyses.
A paediatrician will review data for each child who died,
or is thought to have neurosensory disability or other dis-
ability. If there is any uncertainty, a second independent
expert will review the data, and the outcome will be deter-
mined by consensus. To check for consistency, the second
expert will also review data for a random 10% sample of
these children. An obstetrician will review data for women
who died or had serious morbidity. If there is any uncer-
tainty, a second independent expert will review the data,
and the outcome will be determined by consensus.BMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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Planned analyses
Completeness of follow up at each participating centre
will be described. Centres that return data for either >20%
of all families selected for follow up, or >20% of families
where the mother was randomised before birth, will be
included in the main analyses. Characteristics at trial entry
and outcome at discharge from hospital will be compared
for women and children who were successfully contacted,
those lost to follow up, and the trial overall. How and
when each family was contacted, and what information is
available for each person will be presented.
The main analyses of primary and secondary measures of
outcome will be based on the groups as randomly
allocated regardless of the amount of magnesium received
(an intention to treat comparison).
The analysis of children's death alone will include all
deaths and will take account of the age at death, using
logrank survival analysis. This will allow for the fact that
different children were of variable age when last known to
be alive. Cause of death will be classified [32,33] and,
where possible, presented, as will information about dis-
ability prior to death.
The groups will be compared for each type of neurosen-
sory disability, as defined above, and for children with
multiple disabilities. Mortality and disability by gestation
at birth will be presented.
For the primary outcome statistical significance will be
taken as the 5% level, and for secondary outcomes the 1%
level. The main analyses will be by outcome for each preg-
nancy. For multiple births outcome will be taken as the
worst for any of the children.
We will compare data from those children who were sub-
ject to formal neurodevelopmental testing. As such infor-
mation will be available for screen positive children, but
for only a sample of screen negative children, these scores
will have an artificially truncated distribution. The
median and distribution of scores will be compared
between the treatment groups, for each age of assessment.
Whenever possible, numerical information on develop-
mental progress will be converted to a z-score using local
control data. If there are no local data, we will use the
overall mean and SD to compute a z-score.
We expect to have detailed information on at least 2500
children assessed using the full ASQ questionnaire. The
aim is to compare the progress being made by children in
the two treatment groups using a rank scoring approach.
This will not assume that the spread of development is
normally distributed. To allow for the fact that children
will be tested at different ages, each will be 'scored' by how
many points s/he scored above or below the cut off for
that domain for a child of that age (after adjustment for
gestation at birth if <24 months). Children for whom we
have only a short ASQ will be excluded from this analysis,
as will those whose assessment was outside the appropri-
ate time window.
The possible influence of dose of magnesium sulphate to
which the child was exposed between trial entry and deliv-
ery will be explored, recognising that this dose may be
influenced by the developing clinical situation. The full
plan for this analysis will be formulated before the data
are unblinded.
For the women, deaths will be presented as a graph of
cumulative mortality. Causes of death will be described.
Sensitivity and subgroup analyses
Sensitivity analyses for the composite primary outcome of
death or neurosensory disability for the child will be:
• excluding children classified as having 'likely disability'
• including children whose death or neurosensory disabil-
ity originated during conception or embryogenesis
• excluding data from centres where <90% of randomised
children were selected for follow up, and selection for fol-
low up was not based on a time frame
• including data from centres excluded from the main
analyses because a high proportion (≥80%) could not be
contacted
• considering each child of multiple births rather than just
the one with the worst outcome
Subgroup analyses for the composite primary outcome of
death or neurosensory disability for the child will be by:
• severity of the mother's pre-eclampsia at trial entry
(severe, moderate, mild)
• whether magnesium sulphate had been given in the 48
hours before trial entry
• gestation at birth (<34 weeks, ≥34 weeks)
• perinatal mortality in the country (low, medium or
high)
• whether the mother received trial treatment by the intra-
muscular or the intravenous route
• multiple or singleton birthsBMC Pregnancy and Childbirth 2004, 4 http://www.biomedcentral.com/1471-2393/4/5
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• degree of difficulty in data collection (possible at the
first attempt, reminders, or indirect contact only).
Severity of pre-eclampsia is defined in fig [1]. Severe pre-
eclampsia is as defined in the original trial protocol. The
definition of moderate and mild pre-eclampsia was
agreed (although not published) before the final analysis
of outcome at discharge from hospital. These two groups
were previously reported as 'non-severe' pre-eclampsia
[12]. Perinatal mortality for each country will be as
reported by WHO, [34] as it was in the analysis of out-
come at discharge from hospital [12]. Low perinatal
mortality will be taken <20 deaths/1000 births, moderate
as 20–40/1000 births and high as >40/1000 births.
For the women, subgroup analyses for the main outcome
of death or serious morbidity will be by:
• severity of pre-eclampsia at trial entry (see Box 1)
• gestation at trial entry (<34 weeks, ≥34 weeks)
• perinatal mortality in the country (low, medium or
high)
Additional analyses will evaluate performance of the full
ASQ and the shortened ASQ.
Trial management
Magpie Trial follow up study management group
This group meets every 2–3 months to assist with day to
day running of the trial, and to prepare reports for the
steering committee. Membership: Douglas Altman1, Nina
Armstrong2, Mike Clarke3, Lelia Duley2, Barbara Farrell
(Chair)2, Alastair Gray4, Edmund Hey5, James Neilson6,
Judit Simon4, Rebecca Smyth2, Patsy Spark2 and Ly-Mee
Yu1.
1Centre for Statistics in Medicine, Oxford; 2Magpie Trial
Co-ordinating Centre; 3UK Cochrane Centre, Oxford;
4Centre for Health Economics Research, Oxford;
5paediatrician, Newcastle; 6Department of Obstetrics and
Gynaecology, Liverpool.
Magpie Trial follow up study steering committee
The overall progress of the follow up study will be moni-
tored by a scientific and administrative steering commit-
tee. Membership: Douglas Altman, Rory Collins, Lelia
Duley, Richard Lilford, Jack Moodley, James Neilson, Ian
Roberts, Stephen Robson, Peter Rubin (chair), James
Thornton, Sara Twaddle, and Isabel Walker. Observers are
Anna Karaoglou, Barbara Farrell, a representative from the
Department for International Development and José Vil-
lar. The UK Medical Research Council convenes this
committee.
Statisticians
Douglas Altman, Ly-Mee Yu. Centre for Statistics in Med-
icine, Oxford.
Publication plan
The success of the Magpie Trial Follow Up Study depends
upon the active collaboration of a large number of people,
particularly the co-ordinators and other staff at each par-
ticipating centre. For this reason, authorship of presenta-
tions and reports related to the study will be in the name
of the collaborative group. The final Follow Up Study
results paper will name local co-ordinators as well as
those involved in central co-ordination and trial manage-
ment. Co-ordinators who provided data will be named,
even if all woman and children for whom they collected
data were excluded from the analyses. Certificates of col-
laboration will be provided to those who have made a
substantial contribution but whose name is not on the
final report.
Papers on other aspects of the follow up study will be pub-
lished with those who made substantive contributions
being named as authors. These papers will make appropri-
ate acknowledgement of the contribution of the collabo-
rative group.
Discussion
The Magpie Trial Follow Up Study was launched in March
2002, and now involves collaborators in 19 countries.
Data collection will close at the end of 2003, and results
are expected to be available by the end of 2004.
Funding
The Follow Up Study is funded by the MRC and the
Department for International Development, with support
from WHO.
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Appendix 3 Paediatric assessment form [see Additional
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Appendix 4 Woman's questionnaire [see Additional file:
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